MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Danaher Corp

Slēgts

SektorsVeselības aprūpe

205.16 2.59

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

199.35

Max

205.3

Galvenie mērījumi

By Trading Economics

Ienākumi

268M

1.1B

Pārdošana

738M

6.5B

P/E

Sektora vidējais

38.752

63.778

EPS

2.14

Dividenžu ienesīgums

0.62

Peļņas marža

16.611

Darbinieki

61,000

EBITDA

-230M

1.4B

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+28.05% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.62%

2.39%

Nākamie ieņēmumi

2025. g. 22. apr.

Nākamais dividenžu datums

2025. g. 25. apr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-16B

147B

Iepriekšējā atvēršanas cena

202.57

Iepriekšējā slēgšanas cena

205.16

Ziņu noskaņojums

By Acuity

33%

67%

106 / 386 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bearish Evidence

Danaher Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 5. febr. 12:54 UTC

Peļņas

Johnson Controls Names Weidemanis CEO, Logs 1Q Income Growth

2025. g. 29. janv. 11:44 UTC

Peļņas

Danaher 4Q Revenue Rises on Gains in Life Sciences, Biotech

2024. g. 22. okt. 10:35 UTC

Peļņas

Danaher 3Q EPS, Sales Top Views on Strong Cepheid Test Demand

2024. g. 23. jūl. 10:55 UTC

Peļņas

Danaher Expects 3Q Core Sales Drop, Backs 2024 Guidance

2025. g. 29. janv. 15:25 UTC

Tirgus saruna
Peļņas

Danaher's 2025 Sales Guidance Disappoints -- Market Talk

2025. g. 29. janv. 13:56 UTC

Top Ziņas
Peļņas

Danaher Had an Unusual Quarter. The Stock Is Down. -- Barrons.com

2025. g. 29. janv. 11:08 UTC

Peļņas

Danaher Sees 2025 Bioprocessing Core Revenue Growth 6%-7% >DHR

2025. g. 29. janv. 11:07 UTC

Peļņas

Danaher Sees 2025 Adjusted Operating Profit Margin About 28.5% >DHR

2025. g. 29. janv. 11:07 UTC

Peļņas

Danaher: Expect to Return to Growth, Build Back to Normal Market Conditions in 2025 >DHR

2025. g. 29. janv. 11:02 UTC

Peļņas

Danaher Sees 2025 Adjusted Core Revenue Up About 3% >DHR

2025. g. 29. janv. 11:01 UTC

Peļņas

Danaher Sees 1Q Adjusted Core Revenue Down Low-Single Digits >DHR

2025. g. 29. janv. 11:01 UTC

Peļņas

Danaher 4Q Operating Cash Flow $2B, Free Cash Flow $1.5B >DHR

2025. g. 29. janv. 11:00 UTC

Peļņas

Danaher 4Q Adjusted Core Revenue Rose 1% >DHR

2025. g. 29. janv. 11:00 UTC

Peļņas

Danaher 4Q Cont Ops EPS $1.49 >DHR

2025. g. 29. janv. 11:00 UTC

Peļņas

Danaher 4Q Net $1.09B >DHR

2025. g. 29. janv. 11:00 UTC

Peļņas

Danaher 4Q EPS $1.49 >DHR

2025. g. 29. janv. 11:00 UTC

Peļņas

Danaher 4Q Adj EPS $2.14 >DHR

2025. g. 29. janv. 11:00 UTC

Peļņas

Danaher 4Q Sales $6.5B >DHR

2024. g. 22. okt. 10:02 UTC

Peļņas

Danaher 3Q Adjusted Core Revenue Rose 0.5% >DHR

2024. g. 22. okt. 10:02 UTC

Peļņas

Danaher Still Sees 2024 Adjusted Core Revenue Down Low-Single Digits >DHR

2024. g. 22. okt. 10:01 UTC

Peļņas

Danaher Sees 4Q Adjusted Core Revenue Down Low-Single Digits >DHR

2024. g. 22. okt. 10:00 UTC

Peļņas

Danaher 3Q Operating Cash Flow $1.5B, Adjusted Free Cash Flow $1.2B >DHR

2024. g. 22. okt. 10:00 UTC

Peļņas

Danaher 3Q Sales $5.8B >DHR

2024. g. 22. okt. 10:00 UTC

Peļņas

Danaher 3Q EPS $1.12 >DHR

2024. g. 22. okt. 10:00 UTC

Peļņas

Danaher 3Q Adj EPS $1.71 >DHR

2024. g. 22. okt. 10:00 UTC

Peļņas

Danaher 3Q Net $818M >DHR

2024. g. 22. okt. 10:00 UTC

Peļņas

Danaher 3Q Cont Ops EPS $1.12 >DHR

2024. g. 23. jūl. 12:39 UTC

Top Ziņas
Peļņas

Danaher Stock Surges. More Than Earnings Are Driving It Higher. -- Barrons.com

2024. g. 23. jūl. 10:05 UTC

Peļņas

Danaher 2Q Adjusted Core Revenue Fell 3.5% >DHR

2024. g. 23. jūl. 10:05 UTC

Peļņas

Danaher Sees 2024 Adjusted Core Revenue Down Low-Single Digits >DHR

Salīdzinājums

Cenas izmaiņa

Danaher Corp Prognoze

Cenas mērķis

By TipRanks

28.05% augšup

Prognoze 12 mēnešiem

Vidējais 262.71 USD  28.05%

Augstākais 300 USD

Zemākais 240 USD

Pamatojoties uz 17 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Danaher Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

17 ratings

13

Pirkt

4

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

199.78 / 210.26Atbalsts un pretestība

Īstermiņā

Strong Bearish Evidence

Vidējā termiņā

Weak Bearish Evidence

Ilgtermiņā

Bearish Evidence

Noskaņojums

By Acuity

106 / 386 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.